Hewlett Hopes Sprin...
Technology: Computer Software & Services
ActivIdentity Corporation (ACTI: NASDAQ)
$3.24 0.00 | 0.00%
12/16/10 - 04:00 PM ET
26.16K / 554.00K
Vol / Avg. Vol:3.24 / 3.24
Open / Prev. Close:3.24 - 3.25
Today's Range:1.77 - 3.33
52 Wk Range:37.87%
Performance YTD:TheStreet Rating:
Portfolios with ACTI
- Portfolio NameUser Type
- UserSUPRATRADE HOT STOCKS (BUY ...
- Userdenisdjdss
- UserGavIsyhs
- UserRegisters' Picks
- Userrichard1022 Portfolio 1
- UserDuff
- Userbigpaul71132003 Portfolio 1
- UserVaRoommm13
- Userwkm
- Userlexus814 Portfolio 1
Latest ACTI Headlines from TheStreet
- Consumer Data in Focus in Coming Week 05.07.11 | 10:05 am
- ActivIdentity Soars; Global Payments Slides 10.11.10 | 08:10 pm
- ActivIdentity Buys CoreStreet For $20 Million 12.14.09 | 08:12 am
- Stocks Fight Off Fannie, Freddie 08.20.08 | 05:08 pm
- What's the Next Verse for Activision?
03.18.08 | 09:03 am - Tech Security's Leaders Looking Strong 10.12.07 | 02:10 pm
- Friday's Daily Blog Watch 05.02.07 | 09:05 pm
- Tuesday's Small-Cap Winners & Losers 10.24.06 | 02:10 pm
- Tuesday's Tech Winners & Losers 10.24.06 | 02:10 pm
- Cramer's Top 10 Takeover Candidates 07.28.06 | 10:07 am
Press Releases for ACTI
- Early Versus Delayed Treatment With Laquinimod Demonstrated Significant Reduction In Risk Of Disability Progression – Results Of Three-Year ALLEGRO Study In Relapsing-Remitting Multiple Sclerosis - Business Wire 03.21.13 | 08:03 am
- First Patient Enrolled In Third Phase III Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis - Business Wire 03.06.13 | 08:03 am
- Phase IIa Laquinimod Trial Results Show Positive Data For Potential Use In Active Crohn's Disease - Business Wire 10.22.12 | 09:10 am
- Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis - Business Wire 08.08.12 | 08:08 am
- Phase III Study Of Teva's Oral Laquinimod Published In The New England Journal Of Medicine Demonstrates Clinical Benefits For Multiple Sclerosis Patients - Business Wire 03.15.12 | 08:03 am
- Results Of Phase III BRAVO Trial Reinforce Unique Profile Of Laquinimod For Multiple Sclerosis Treatment - Business Wire 08.01.11 | 07:08 am
- Oral Laquinimod For Multiple Sclerosis Treatment Significantly Reduced Disease Activity And Disability Progression While Providing Good Safety And Tolerability - Business Wire 04.11.11 | 06:04 pm
- ALLEGRO Lead Investigator Professor Giancarlo Comi Discusses The Initial Study Results - Business Wire 12.09.10 | 01:12 am
- Faruqi & Faruqi, LLP Announces Shareholder Investigation Related To The Acquisition Of ActivIdentity Corp. - ACTI - Business Wire 11.05.10 | 05:11 pm
- Bull & Lifshitz, LLP Announces Investigation Of The Acquisition Of ActivIdentity Corporation - Business Wire 10.20.10 | 04:10 pm
Partner Headlines for ACTI
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 05.26.10 | 09:05 am
